{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:22:10Z","timestamp":1770279730551,"version":"3.49.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejphar.2020.173242","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T11:14:15Z","timestamp":1591182855000},"page":"173242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis"],"prefix":"10.1016","volume":"881","author":[{"given":"Michael","family":"Soeberdt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Abels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173242_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/exd.13987","article-title":"Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases","author":"Abels","year":"2019","journal-title":"Exp. Dermatol."},{"issue":"10","key":"10.1016\/j.ejphar.2020.173242_bib2","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.peptides.2011.09.003","article-title":"Gastrin-releasing peptide induces itch-related responses through mast cell degranulation in mice","volume":"32","author":"Andoh","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2020.173242_bib3","series-title":"Topical JAK Inhibitor Active in Atopic Dermatitis \u2013 Significant Improvement in Multiple Endpoints after 4 Weeks with Ruxolitinib Cream","author":"Bankhead","year":"2018"},{"issue":"14","key":"10.1016\/j.ejphar.2020.173242_bib4","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173242_bib5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2007.01.007","article-title":"Treatment of pruritus with topically applied opiate receptor antagonist","volume":"56","author":"Bigliardi","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib6","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173242_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2133.2008.08449.x","article-title":"Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars","volume":"158","author":"Cheng","year":"2008","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173242_bib8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaad.2019.09.014","article-title":"Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in epidermolysis bullosa patients: a randomized clinical trial","volume":"82","author":"Chiou","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173242_bib9","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nn.3144","article-title":"Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology","volume":"15","author":"Chiu","year":"2012","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173242_bib10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.neuron.2018.03.023","article-title":"Peripheral and central mechanisms of itch","volume":"98","author":"Dong","year":"2018","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173242_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamadermatol.2018.4093","article-title":"Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review","volume":"155","author":"Ekelem","year":"2019","journal-title":"JAMA dermatology"},{"issue":"3","key":"10.1016\/j.ejphar.2020.173242_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jdermsci.2016.09.008","article-title":"Topical nalfurafine exhibits anti-inflammatory and anti-pruritic effects in a murine model of AD","volume":"84","author":"Elliott","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.ejphar.2020.173242_bib13","series-title":"Assessment Report Winfuran. Procedure No. EMEA\/H\/C\/002683\/0000","author":"EMA","year":"2013"},{"key":"10.1016\/j.ejphar.2020.173242_bib14","series-title":"Staquis","author":"EMA","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173242_bib15","series-title":"FDA Approves Eucrisa for Eczema","author":"FDA","year":"2016"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173242_bib16","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41598-019-38858-3","article-title":"Brain allopregnanolone induces marked scratching behaviour in diet-induced atopic dermatitis mouse model","volume":"9","author":"Fujii","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173242_bib17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1124\/jpet.115.223784","article-title":"Topically administered Janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis","volume":"354","author":"Fukuyama","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173242_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/1346-8138.12534","article-title":"Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial","volume":"41","author":"Furue","year":"2014","journal-title":"J. Dermatol."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173242_bib19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/abd1806-4841.20164211","article-title":"Atopic dermatitis: allergic dermatitis or neuroimmune dermatitis?","volume":"91","author":"Gaspar","year":"2016","journal-title":"An. Bras. Dermatol."},{"issue":"10","key":"10.1016\/j.ejphar.2020.173242_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/exd.12798","article-title":"Self-maintenance of neurogenic inflammation contributes to a vicious cycle in skin","volume":"24","author":"Gouin","year":"2015","journal-title":"Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173242_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaad.2016.04.001","article-title":"OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study","volume":"75","author":"Hanifin","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173242_bib22","first-page":"853","volume":"10","author":"Herzog","year":"2011","journal-title":"J. Drugs Dermatol. JDD: J. Drugs Dermatol. JDD"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib23","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1034\/j.1600-0625.2002.110508.x","article-title":"Efficacy of naltrexone on acetylcholine\u2010induced alloknesis in atopic eczema","volume":"11","author":"Heyer","year":"2002","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2020.173242_bib24","doi-asserted-by":"crossref","first-page":"172702","DOI":"10.1016\/j.ejphar.2019.172702","article-title":"Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis","volume":"864","author":"Inan","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173242_bib25","series-title":"Delgocitinib - Japan Tobacco\/LEO Pharma","author":"Insight","year":"2019"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173242_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/jpet.113.205542","article-title":"Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model","volume":"346","author":"Ishii","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173242_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1152\/physiol.00007.2011","article-title":"Itch signaling in the nervous system","volume":"26","author":"Jeffry","year":"2011","journal-title":"Physiology"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173242_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178991","article-title":"Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses","volume":"12","author":"Kamimura","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173242_bib29","first-page":"e21","article-title":"Pruritus in inflammatory skin diseases - a brain issue?","volume":"28","author":"Kilic","year":"2019","journal-title":"Exp. Dermatol."},{"issue":"3 Pt 2","key":"10.1016\/j.ejphar.2020.173242_bib30","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/S0091-6749(99)70052-7","article-title":"Itching and the atopic skin","volume":"104","author":"Koblenzer","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173242_bib31","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173242_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000341268","article-title":"Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients","volume":"36","author":"Kumagai","year":"2012","journal-title":"Am. J. Nephrol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2340\/00015555-2595","article-title":"Opioid receptors in psoriatic skin: relationship with itch","volume":"97","author":"Kupczyk","year":"2017","journal-title":"Acta Derm. Venereol."},{"issue":"Suppl. 3","key":"10.1016\/j.ejphar.2020.173242_bib34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1529-8027.2012.00430.x","article-title":"Skin biopsy in painful and immune-mediated neuropathies","volume":"17","author":"Lauria","year":"2012","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.ejphar.2020.173242_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2020.173242_bib36","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00424-013-1284-2","article-title":"New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?","volume":"465","author":"Liu","year":"2013","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173242_bib37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2011.08.043","article-title":"Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids","volume":"147","author":"Liu","year":"2011","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ejphar.2020.173242_bib38","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1468-3083.2009.03129.x","article-title":"Efficacy of oral naltrexone on pruritus in atopic eczema: a double\u2010blind, placebo\u2010controlled study","volume":"23","author":"Malekzad","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173242_bib39","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2340\/00015555-1159","article-title":"Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study","volume":"91","author":"Matterne","year":"2011","journal-title":"Acta Derm. Venereol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2340\/00015555-1572","article-title":"Incidence and determinants of chronic pruritus: a population-based cohort study","volume":"93","author":"Matterne","year":"2013","journal-title":"Acta Derm. Venereol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib41","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.jaci.2017.12.1002","article-title":"New mechanism underlying IL-31\u2013induced atopic dermatitis","volume":"141","author":"Meng","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejphar.2020.173242_bib42","series-title":"Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis","author":"Menlo Therapeutics Inc","year":"2018"},{"key":"10.1016\/j.ejphar.2020.173242_bib43","series-title":"Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis","author":"Menlo Therapeutics Inc","year":"2020"},{"key":"10.1016\/j.ejphar.2020.173242_bib44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000446040","article-title":"Itch management: topical agents","volume":"50","author":"Metz","year":"2016","journal-title":"Curr. Probl. Dermatol."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173242_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-018-0097-7","article-title":"Psychogenic itch","volume":"8","author":"Misery","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"6135","key":"10.1016\/j.ejphar.2020.173242_bib46","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1126\/science.1233765","article-title":"The cells and circuitry for itch responses in mice","volume":"340","author":"Mishra","year":"2013","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173242_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.alit.2016.08.013","article-title":"Brain mechanism of itch in atopic dermatitis and its possible alteration through non-invasive treatments","volume":"66","author":"Mochizuki","year":"2017","journal-title":"Allergol. Int."},{"issue":"22","key":"10.1016\/j.ejphar.2020.173242_bib48","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1016\/j.bmcl.2015.09.040","article-title":"Conformationally restricted \u03ba-opioid receptor agonists: synthesis and pharmacological evaluation of diastereoisomeric and enantiomeric decahydroquinoxalines","volume":"25","author":"Molenveld","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"3","key":"10.1016\/j.ejphar.2020.173242_bib49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173242_bib50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1346-8138.14322","article-title":"Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis","volume":"45","author":"Nakagawa","year":"2018","journal-title":"J. Dermatol."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173242_bib51","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/1346-8138.13231","article-title":"Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: results from a randomized, vehicle-controlled exploratory trial","volume":"43","author":"Nemoto","year":"2016","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000484407","article-title":"Emerging treatment options in atopic dermatitis: topical therapies","volume":"233","author":"Nygaard","year":"2017","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173242_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdermsci.2017.05.015","article-title":"Echinacea purpurea-derived alkylamides exhibit potent anti-inflammatory effects and alleviate clinical symptoms of atopic eczema","volume":"88","author":"Ol\u00e1h","year":"2017","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib54","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.12935","article-title":"Are itch and scratching the nausea and vomiting of skin?","volume":"25","author":"Ostadhadi","year":"2016","journal-title":"Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173242_bib55","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173242_bib56","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: end of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173242_bib57","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2020.01.056","article-title":"Serlopitant for psoriatic pruritus: a phase 2 randomized, double-blind, placebo-controlled clinical trial","volume":"82","author":"Pariser","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"10.1016\/j.ejphar.2020.173242_bib58","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1517\/14656566.2010.484420","article-title":"Therapy of pruritus","volume":"11","author":"Patel","year":"2010","journal-title":"Expet Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib59","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-1353","article-title":"Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm. Venereol."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173242_bib60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1152\/physrev.00026.2005","article-title":"Neuronal control of skin function: the skin as a neuroimmunoendocrine organ","volume":"86","author":"Roosterman","year":"2006","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173242_bib61","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/1346-8138.14979","article-title":"Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: a phase 2, randomized, double-blind, placebo-controlled study","volume":"46","author":"Saeki","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ejphar.2020.173242_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/exd.13977","article-title":"Why we scratch: function and dysfunction","author":"Sanders","year":"2019","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2020.173242_bib63","series-title":"Sienna Biopharmaceuticals Announces its Topical, Non-steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019","author":"Sienna Biopharmaceuticals","year":"2018"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib64","first-page":"457","article-title":"Neuroendocrinology of the skin","volume":"21","author":"Slominski","year":"2000","journal-title":"Endocr. Rev."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173242_bib65","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/acs.jmedchem.6b01868","article-title":"Design and synthesis of enantiomerically pure decahydroquinoxalines as potent and selective kappa-opioid receptor agonists with anti-Inflammatory activity in vivo","volume":"60","author":"Soeberdt","year":"2017","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib66","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.jid.2018.03.395","article-title":"388 A phase Ib trial in AD patients evaluating safety, tolerability, pharmacokinetics and efficacy of topical formulations containing the kappa-opioid receptor agonist WOL071-007","volume":"138","author":"Soeberdt","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"500","key":"10.1016\/j.ejphar.2020.173242_bib67","doi-asserted-by":"crossref","first-page":"eaav5464","DOI":"10.1126\/scitranslmed.aav5464","article-title":"Inhibition of natriuretic peptide receptor 1 reduces itch in mice","volume":"11","author":"Solinski","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173242_bib68","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejphar.2020.173242_bib69","article-title":"Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus","author":"Stander","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173242_bib70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the international forum for the study of itch","volume":"87","author":"Stander","year":"2007","journal-title":"Acta Derm. Venereol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib71","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","article-title":"Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial","volume":"80","author":"St\u00e4nder","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173242_bib72","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2704","article-title":"Involvement of micro-opioid receptors and kappa-opioid receptors in itch-related scratching behaviour of imiquimod-induced psoriasis-like dermatitis in mice","volume":"97","author":"Takahashi","year":"2017","journal-title":"Acta Derm. Venereol."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173242_bib73","doi-asserted-by":"crossref","first-page":"8625","DOI":"10.1038\/s41598-019-44866-0","article-title":"Homeostatic pruning and activity of epidermal nerves are dysregulated in barrier-impaired skin during chronic itch development","volume":"9","author":"Takahashi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.173242_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/exd.13975","article-title":"Cutaneous nociception: role of keratinocytes","author":"Talagas","year":"2019","journal-title":"Exp. Dermatol."},{"issue":"11","key":"10.1016\/j.ejphar.2020.173242_bib75","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/exd.13392","article-title":"Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural system","volume":"26","author":"Tarrason","year":"2017","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejphar.2020.173242_bib76","series-title":"Tioga Pharmaceuticals' Asimadoline Reduces Nighttime Itching and Improves Disease-Related Quality of Life in Patients with Atopic Dermatitis","author":"Tioga Pharmaceuticals","year":"2017"},{"issue":"9","key":"10.1016\/j.ejphar.2020.173242_bib77","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/sj.jid.5700942","article-title":"Possible roles of epidermal opioid systems in pruritus of atopic dermatitis","volume":"127","author":"Tominaga","year":"2007","journal-title":"J. Invest. Dermatol."},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2020.173242_bib78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2011.09.169","article-title":"The kappa opioid receptor agonist SA14867 has antinociceptive and weak sedative effects in models of acute and chronic pain","volume":"671","author":"Tsukahara-Ohsumi","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173242_bib79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/qjmed\/hcg002","article-title":"Itch: scratching more than the surface","volume":"96","author":"Twycross","year":"2003","journal-title":"QJM"},{"issue":"12","key":"10.1016\/j.ejphar.2020.173242_bib80","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","article-title":"\u03ba-Opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstr\u00f6m","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173242_bib81","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.ejphar.2020.173242_bib82","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMcp1208814","article-title":"Clinical practice. Chronic pruritus","volume":"368","author":"Yosipovitch","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib83","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2340\/00015555-2893","article-title":"Early relief of pruritus in atopic dermatitis with crisaborole ointment, A non-steroidal, phosphodiesterase 4 inhibitor","volume":"98","author":"Yosipovitch","year":"2018","journal-title":"Acta Derm. Venereol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173242_bib84","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920303344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920303344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:41:20Z","timestamp":1757976080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920303344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":84,"alternative-id":["S0014299920303344"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173242","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173242"}}